Company / EPS (Diluted)
Viking Therapeutics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.91
FY2025
5-year range
-$0.91 / -$0.54
FY2021-FY2025
Trend
-1.1%
vs FY2024
Sector context
#84 of 204
Health Care
What the data says
At $-0.91, Viking Therapeutics, Inc.'s eps (diluted) ranks #84 of 204 in the Health Care sector. Declined from $-0.71 to $-0.91 over the past 2 years.
Based on SEC 10-K filings.
-0.91 in FY2025.
Declined from $-0.71 to $-0.91 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 204 in Health CareTop 41% of 204This company -$0.91 Sector average -$0.89
▼
-2.7% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 1.1% year-over-year.
- Ranks #84 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.91 | -1.1% |
| FY2024 | -$0.90 | -26.8% |
| FY2023 | -$0.71 | +0.0% |
| FY2022 | -$0.71 | -31.5% |
| FY2021 | -$0.54 | -50.0% |
| FY2020 | -$0.36 | +5.3% |
| FY2019 | -$0.38 | +51.9% |
| FY2018 | -$0.79 | +12.2% |
| FY2017 | -$0.90 | +75.5% |
| FY2016 | -$3.68 | +29.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026